IBD-Associated Arthritis News

Switching to biosimilar Remicade was safe and noninferior to continued treatment with the originator product across multiple indications, including inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and chronic plaque psoriasis, according to data from the NOR-SWITCH study presented at UEG Week 2016.

The International Autoimmunity Summit gathered several hundred experts who span the spectrum of autoimmune diseases, which are often referred to as immune-mediated inflammatory diseases. These included many rheumatologists, as well as dermatologists, gastroenterologists, allergists and advanced practitioners who are all engaged in the care and research of these disorders.

A new industry body, the British Biosimilars Association, has been launched to promote the use of biosimilar drug treatments in the United Kingdom, according to a press release.

Infection with parasitic worms can reduce intestinal inflammatory responses associated with inflammatory bowel disease by promoting changes in the gut microbiome that enable beneficial bacterial communities to thrive, according to new research published in the journal Science.

Members of the FDA Arthritis Advisory Committee voted positively today for the recommendation to approve the biologics license application of Celltrion’s CT-P13 biosimilar to infliximab. If approved, CT-P13 would be the first biosimilar monoclonal antibody to be approved for use in the United States.

Amgen recently announced in a press release that the FDA has accepted its biologics license application for ABP 501, Amgen’s biosimilar to adalimumab, for review.

The anti-pneumococcal polysaccharide vaccine appears to be preserved for at least 10 years among patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and inflammatory bowel disease-associated spondyloarthritis, although efficacy may be diminished by methotrexate use, according to researchers from the Department of Rheumatology in the Tel Aviv Medical Center, Sackler School of Medicine at Tel Aviv University, Tel Aviv, Israel.

The American College of Rheumatology Annual Meeting in San Francisco begins on Nov. 7, and Healio Rheumatology will cover the event and its many topics — ranging from rheumatoid arthritis to spondyloarthropathies, osteoarthritis, systemic lupus erythematosus, scleroderma, vasculitis, fibromyalgia, juvenile arthritis and much more— throughout the week.

Welcome to the Premier Issue of Healio Rheumatology, a print publication based on the most important news as measured by the online preferences of your colleagues. In this issue, you will find the most-read content from readers of Healio.com/Rheumatology, our online news site for rheumatology. We call this unique approach to issue content selection “Peer-Tested Content” and we believe the approach will provide you the best and most valuable content in your area of expertise.

SLACK Incorporated, publisher of Healio.com, is set to expand its series of web-first news magazines delivering unique peer-tested content. Healio Rheumatology will compile the most-read content from Healio.com based on website metrics, and distribute it in a print news magazine reaching 6,100 U.S. physicians, including the universe of U.S. rheumatologists.